- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Rob Nolan Discusses Behavioral Foundations of eCounseling Programs
The use of technology in behavioral interventions is exciting, but it is important to integrate the underlying principles of behavioral science when developing counseling interventions, explained Rob Nolan, PhD, CPsych, director of Cardiac eHealth at the Peter Munk Cardiac Centre and clinical psychologist and scientist at the Toronto General Research Institute, at the American College of Cardiology 66th Scientific Session, where he presented the results of the REACH eCounseling trial.
The use of technology in behavioral interventions is exciting, but it is important to integrate the underlying principles of behavioral science when developing counseling interventions, explained Rob Nolan, PhD, CPsych, director of Cardiac eHealth at the Peter Munk Cardiac Centre and clinical psychologist and scientist at the Toronto General Research Institute, at the American College of Cardiology 66th Scientific Session, where he presented the results of the REACH eCounseling trial.
Transcript (slightly modified)
How can clinicians get the most benefit out of new technologies like eCounseling?
I think what’s important for us is, when we were starting REACH, we saw that technology was certainly growing exponentially, right. There’s a lot of interest in using different types of technological supports, whether it’s text messaging, wearable devices to monitor our responses. I think all that is superb, but I think what worked in REACH was that we were able to extract the evidence-based components of the behavioral counseling models that have been shown to be effective in the past, and I think combining the two really optimizes our interventions.
I think without really having a specific model of behavioral counseling, the technology alone, I don’t think that typically will sustain the change. Also, the kinds of comparisons that we could make from trial to trial really will vary and we’ll have that ongoing problem of heterogeneity of treatment effects, because there won’t be any consistency. I think the counseling or clinically applied science is really important to integrate here for that reason.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More
